Warfarin Labeling Change: Genetic Test Firms Anxiously Await FDA Action
This article was originally published in The Gray Sheet
Executive Summary
Genetic test makers are lining up in anticipation of an FDA label change for the blood thinner warfarin that could significantly expand the market for companion diagnostics. They might still have a while to wait
You may also be interested in...
Personalized Genetic Test Info Added To Warfarin Drug Labeling
FDA is updating the label for the anti-clotting drug warfarin to inform physicians and patients about the usefulness of genetic testing before beginning therapy, but the agency will wait for data from ongoing studies of the tests before adding stronger recommendations for the tests
Personalized Genetic Test Info Added To Warfarin Drug Labeling
FDA is updating the label for the anti-clotting drug warfarin to inform physicians and patients about the usefulness of genetic testing before beginning therapy, but the agency will wait for data from ongoing studies of the tests before adding stronger recommendations for the tests
C-Path Institute Exec Targets “Points Of Pain” In Device Development
The Critical Path Institute's new Director of Medical Devices and Imaging, Ellen Feigal, MD, is working with device firms to identify key roadblocks to product development and clear the way to regulatory approval for those products